RGNT
Regentis Biomaterials Ltd.
NYSE: RGNT · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$1.80
+1.12% today
Updated 2026-07-30
Market cap
$12.50M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-24.16
Dividend yield
—
52W range
$1 – $9
Volume
6.5M
Regentis Biomaterials Ltd. (RGNT) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$1.80
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.